NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate<
10 Sep 2024

Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate

This award highlights the promise of regenerative medicine technology, including Neurona’s pipeline of cell therapy candidates for patients with epilepsy and other CNS diseases.
Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy<
27 Aug 2024

Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy

Joins ahead of lead development candidate Potravitug entering Phase III trial
LAVA Reports Second Quarter 2024 Financial Results and Business Update<
20 Aug 2024

LAVA Reports Second Quarter 2024 Financial Results and Business Update

Next data update for LAVA-1207 program expected in Q4 2024
Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor<
20 Aug 2024

Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor

Adcendo will obtain the exclusive development and commercialization rights for the asset globally, except for the Greater China region.
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update<
13 Aug 2024

Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025

Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors<
08 Aug 2024

Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors

$10 Million Investment Received from Foresite Capital in Extension of Series B Financing
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights<
08 Aug 2024

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Strong Cash Position Expected to Fund Operations into Second Half of 2026
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update<
06 Aug 2024

KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Topline data from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025
Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors<
23 Jul 2024

Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors

Data support advancement of CK-0045 into Phase 2 proof-of-concept studies in individuals with type 2 diabetes and/or obesity
Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs<
23 Jul 2024

Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs

Follows expansion of Xeltis’ clinical presence in the US after recent IDE approval for aXessTM US pivotal trial

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.